Joseph Pearlberg
Directeur/Bestuurslid bij NUVALENT, INC.
Actieve functies van Joseph Pearlberg
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
NUVALENT, INC. | Directeur/Bestuurslid | 01-01-2021 | - |
Independent Dir/Board Member | 01-01-2021 | - | |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
Neomorph, Inc.
Neomorph, Inc. Pharmaceuticals: MajorHealth Technology Neomorph, Inc. is an American venture-backed biotechnology company that focuses on discovering innovative new medicines against 'undruggable' targets to solve critical problems in human health. The company is headquartered in an undisclosed location and has a key collaboration with the Center for Protein Degradation at the Dana Farber Cancer Institute. Neomorph's team is comprised of industry-leading experts in protein degradation and molecular glues who are committed to advancing the science and technology of molecular glue drug discovery. The company's patient-first, science-driven approach is complemented by its dedication to a supportive and collaborative work environment. Neomorph was founded by Eric Fischer, Philip Chamberlain, Scott A. Armstrong, and Benjamin Ebert, with Philip Chamberlain serving as the CEO since incorporation. | Directeur/Bestuurslid | - | - |
Deerfield Management Co. LP (Private Equity)
Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management Co. LP (Private Equity) (Deerfield) is a private equity subsidiary of Deerfield Management Co. LP founded in 1994. The firm is headquartered in the New York. | Private Equity Investor | 01-07-2017 | - |
Loopbaan van Joseph Pearlberg
Eerdere bekende functies van Joseph Pearlberg
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
INFINITY PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-12-2014 | 01-07-2017 |
Sanofi SA | Hoofd Techniek/Wetenschap/O&O | - | - |
Opleiding van Joseph Pearlberg
The University of California, San Francisco | Doctorate Degree |
University of Pennsylvania | Undergraduate Degree |
Harvard University | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 9 |
Frankrijk | 2 |
Operationeel
Corporate Officer/Principal | 2 |
Director/Board Member | 2 |
Doctorate Degree | 2 |
Sectoraal
Health Technology | 6 |
Consumer Services | 4 |
Finance | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
INFINITY PHARMACEUTICALS, INC. | Health Technology |
NUVALENT, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Health Technology |
Neomorph, Inc.
Neomorph, Inc. Pharmaceuticals: MajorHealth Technology Neomorph, Inc. is an American venture-backed biotechnology company that focuses on discovering innovative new medicines against 'undruggable' targets to solve critical problems in human health. The company is headquartered in an undisclosed location and has a key collaboration with the Center for Protein Degradation at the Dana Farber Cancer Institute. Neomorph's team is comprised of industry-leading experts in protein degradation and molecular glues who are committed to advancing the science and technology of molecular glue drug discovery. The company's patient-first, science-driven approach is complemented by its dedication to a supportive and collaborative work environment. Neomorph was founded by Eric Fischer, Philip Chamberlain, Scott A. Armstrong, and Benjamin Ebert, with Philip Chamberlain serving as the CEO since incorporation. | Health Technology |
Sanofi SA | Health Technology |
Deerfield Management Co. LP (Private Equity)
Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management Co. LP (Private Equity) (Deerfield) is a private equity subsidiary of Deerfield Management Co. LP founded in 1994. The firm is headquartered in the New York. | Finance |
- Beurs
- Insiders
- Joseph Pearlberg
- Ervaring